about
CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survivalThe tumor border configuration of colorectal cancer as a histomorphological prognostic indicator.TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancerHeterogeneity analysis of Metastasis Associated in Colon Cancer 1 (MACC1) for survival prognosis of colorectal cancer patients: a retrospective cohort study.Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinomaLoss of tapasin correlates with diminished CD8(+) T-cell immunity and prognosis in colorectal cancer.Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors.DAPK loss in colon cancer tumor buds: implications for migration capacity of disseminating tumor cells.VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancerThe IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice.Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy studyPhenotyping of tumor-associated macrophages in colorectal cancer: Impact on single cell invasion (tumor budding) and clinicopathological outcome.Geographic analysis of RKIP expression and its clinical relevance in colorectal cancer.Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy.Loss of Cdx2 Expression in Primary Tumors and Lymph Node Metastases is Specific for Mismatch Repair-Deficiency in Colorectal CancerColorectal Choriocarcinoma in a Patient with Probable Lynch Syndrome.Intratumoural budding (ITB) in preoperative biopsies predicts the presence of lymph node and distant metastases in colon and rectal cancer patients.Tumor budding in upper gastrointestinal carcinomas.Tumor budding in colorectal cancer--ready for diagnostic practice?Cytokeratin-based assessment of tumour budding in colorectal cancer: analysis in stage II patients and prospective diagnostic experience.Comprehensive assessment of tumour budding by cytokeratin staining in colorectal cancer.Suppression of intratumoral CCL22 by type i interferon inhibits migration of regulatory T cells and blocks cancer progression.Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.Prognostic impact of β-2-microglobulin expression in colorectal cancers stratified by mismatch repair status.CD103 is a hallmark of tumor-infiltrating regulatory T cells.Impact of peritumoral and intratumoral budding in esophageal adenocarcinomas.Next-generation tissue microarray (ngTMA) increases the quality of biomarker studies: an example using CD3, CD8, and CD45RO in the tumor microenvironment of six different solid tumor types.Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study.Digital analysis and epigenetic regulation of the signature of rejection in colorectal cancer.Expression of the hyaluronan-mediated motility receptor RHAMM in tumor budding cells identifies aggressive colorectal cancers.Tumour border configuration in colorectal cancer: proposal for an alternative scoring system based on the percentage of infiltrating margin.The ESRP1-GPR137 axis contributes to intestinal pathogenesis.Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome.A modular approach to suppression assays: TLR ligands, conditioned medium, and viral infection.Correction: DAPK loss in colon cancer tumor buds: implications for migration capacity of disseminating tumor cells.The apoptotic and proliferation rate of tumour budding cells in colorectal cancer outlines a heterogeneous population of cells with various impacts on clinical outcome.Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer.Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer.Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer.Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease.
P50
Q33615807-36C9D7D3-3826-42F3-B733-187FE4AE056AQ34660196-C9FD8260-9E65-42A0-B7C3-404F0A47B28FQ35176169-5C3911C3-B12F-4791-B36C-7BCBDB8D5307Q35211652-228C9853-D453-4E46-81F3-8DF2306FD500Q35551974-8F1FCB85-BFDE-469C-B940-659757BB3DA7Q36001921-83ED4E64-1804-4A52-91EF-592F1E61A290Q36270828-481507FC-EF05-435D-9799-778BB1C53F8BQ36546788-09E1083F-E503-46D8-9F91-7D4BFEAC3D3BQ36561520-C9B61725-3BC7-46E1-BC36-2CF46F52E731Q36597522-7925F536-03EE-4127-88ED-8EB569419E55Q36687229-D94FA152-E085-4931-BF1C-1C1E0A4572A7Q36821128-8B362ADD-9886-49A9-9B9E-65F286ED5BFBQ36896127-B9DFA00B-EC9D-4D4A-BE6B-24C0FCCB4A2EQ37178600-AA07CB68-0C21-4FF4-BFDF-62835F05E7E3Q37226416-5A8C3643-82ED-46AA-9982-001919A4DA6AQ37447203-958D7A50-05F9-4422-8C44-C025DC17C68AQ37594364-0435B094-3FF9-483C-82C1-5E90A2208BC6Q38245240-AF4F81C8-13C9-4545-A63C-42E0B68B6285Q38609953-E7388E1B-CF8B-4615-B089-6B1A892CA8A5Q38647804-588847D9-77D7-493F-AFF8-B3D9D4FD02BEQ38773906-A9DA6818-8D24-431C-AEDD-1A8906D5D32EQ38830643-60322D8A-C0EC-4113-AC4B-AA660608D41AQ38839775-5D280EC8-67EE-4159-9C6A-D7DAEFD8DC5EQ39574963-702C50F0-B76B-4428-BE49-5F7DF96878B0Q39612049-B6898D29-757B-43DF-A44A-58029F099EDCQ39918407-A5A220C8-C2F7-4A53-BA4B-984F05A2D28FQ40108069-DA436946-CAC4-4BAE-ADD7-41B0DB60FCB0Q40258500-98E3EBC6-A6F6-46F6-9E66-9E9061D5B543Q40469741-35B63A36-8660-423F-97F4-534A21FA4B7FQ40560933-EFBC0ECE-C8A3-4DA7-BEB7-96AF8120609CQ41484734-3F6A85AA-FF31-4BAD-9122-CAA56B817EB3Q41991370-06A9EFF9-C8A9-4555-AC66-AF9BE2EF3358Q42153256-65A0CBD7-CBA7-4045-8412-132CF5AC3619Q42209300-23817C00-6EF9-4BA7-A65F-7A678D255699Q42363019-F10F0FE3-3AF1-4E80-9F44-0D093D3B0E07Q43587615-1966BBED-0C70-4758-9E4F-FB877F307ED8Q43909345-74306624-C17B-4482-8264-0EAFECB9E516Q47131106-4C3FE2CC-7EC3-4456-B5EF-A2EFB12E6E50Q47321577-A6280F1F-0A0F-4DFD-9241-A5E6083626EEQ47999192-E1CCFFEA-479D-4970-8E4A-B5EEAD8670A0
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Viktor H Koelzer
@nl
Viktor H Koelzer
@sl
Viktor H. Koelzer
@en
Viktor H. Koelzer
@es
type
label
Viktor H Koelzer
@nl
Viktor H Koelzer
@sl
Viktor H. Koelzer
@en
Viktor H. Koelzer
@es
altLabel
Viktor Koelzer
@en
prefLabel
Viktor H Koelzer
@nl
Viktor H Koelzer
@sl
Viktor H. Koelzer
@en
Viktor H. Koelzer
@es
P214
P106
P1153
25521851600
P21
P214
P2798
P31
P3835
viktor-koelzer2
P496
0000-0001-9206-4885
P734
P735
P7859
viaf-232510928